← Back to patent-cliff list
ST-1703
Tier C — Watch / tradeST-1703
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HER2
Indications (approved)：Solid tumour, Metastatic breast cancer
Regional status
US
-
EU
-
China
Phase II
2022-01-20
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ST-1703?
Approved indications include: Solid tumour, Metastatic breast cancer.
When does the ST-1703 patent expire?
No public expiry year is available for ST-1703 yet; this page updates once verified.
How do I get a quote for ST-1703 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05